Inactive Instrument

BioSpecifics Technologies Corp.

BSTC

US0909311062

Biotechnology & Medical Research

BioSpecifics: 3Q Earnings Snapshot

November 09, 2020 at 08:42 am EST

WILMINGTON, Del. (AP) _ BioSpecifics Technologies Corp. (BSTC) on Monday reported third-quarter profit of $5.4 million.

The Wilmington, Delaware-based company said it had net income of 73 cents per share. Earnings, adjusted for stock option expense, were 79 cents per share.

The biopharmaceutical company posted revenue of $11.3 million in the period.

BioSpecifics shares have increased 55% since the beginning of the year. The stock has climbed 76% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BSTC at https://www.zacks.com/ap/BSTC

Latest news about BioSpecifics Technologies Corp.

Fourth Amended Joint Reorganization Plan Approved for Endo International plc	Mar. 22	CI
Fourth Amended Joint Reorganization Plan Filed by Endo International plc	Mar. 18	CI
Third Amended Joint Reorganization Plan and Disclosure Statement Filed by Endo International plc	Feb. 20	CI
Motion for Exclusivity Period Extension Approved For Endo International plc	Jan. 24	CI
Combined Hearing for Disclosure Statement and Plan Approved for Endo International plc	Jan. 12	CI
Second Amended Joint Reorganization Plan and Disclosure Statement Filed by Endo International plc	Jan. 09	CI
First Amended Reorganization Plan and Disclosure Statement Filed by Endo International plc	Jan. 05	CI
Joint Reorganization Plan and Disclosure Statement Filed by Endo International plc	Dec. 18	CI
Third Motion for Exclusivity Period Extension Approved For Endo International plc	Nov. 15	CI
Second Motion for Exclusivity Period Extension Approved For Endo International plc	23-07-31	CI
Two Affiliate Companies Joined Endo International plc Bankruptcy	23-05-25	CI
First Motion for Exclusivity Period Extension Approved For Endo International plc	23-04-03	CI
First Motion for Exclusivity Period Extension Filed by Endo International plc	22-12-13	CI
Motion for Asset Sale Filed by Endo International plc	22-11-22	CI
Motion for Asset Sale Approved for Endo International plc	22-10-27	CI
Motion for Asset Sale Filed by Endo International plc	22-09-22	CI
Motion for De Minimis Assets Sale Filed by Endo International plc	22-09-02	CI
Motion for Joint Administration Approved for Endo International plc	22-08-17	CI
Motion for Joint Administration Filed by Endo International plc	22-08-16	CI
Endo International plc Filed for Bankruptcy	22-08-16	CI
BioSpecifics Technologies Corp. Announces Management Changes	20-12-02	CI
BioSpecifics Technologies Corp.(NasdaqGM:BSTC) dropped from S&P Global BMI Index	20-12-02	CI
BioSpecifics Technologies Corp.(NasdaqGM:BSTC) dropped from S&P TMI Index	20-12-02	CI
BioSpecifics Technologies Corp.(NasdaqGM:BSTC) dropped from Russell 2500 Index	20-12-02	CI
BioSpecifics Technologies Corp.(NasdaqGM:BSTC) dropped from Russell Small Cap Comp Growth Index	20-12-02	CI

Chart BioSpecifics Technologies Corp.

Duration

Period

More charts

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren's contracture and Peyronie's disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs

BioSpecifics Technologies Corp.

Equities

BSTC

US0909311062

Biotechnology & Medical Research

BioSpecifics: 3Q Earnings Snapshot

Latest news about BioSpecifics Technologies Corp.

Chart BioSpecifics Technologies Corp.

Company Profile

Sector Bio Therapeutic Drugs